Does Humana Cover Prolia (Denosumab)?

What Is Prolia and Why Does Insurance Coverage Get Complicated?

Prolia (denosumab 60 mg subcutaneous, every 6 months) is a RANK-ligand inhibitor that reduces osteoclast-mediated bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and subsequent approvals extended its use to men with osteoporosis, patients on long-term glucocorticoid therapy, and patients with bone loss from androgen deprivation or aromatase inhibitor therapy [1]. Because it is a biologic with no small-molecule generic equivalent, it lands in the specialty tier of most drug formularies, triggering prior authorization and, often, step therapy requirements.

The FREEDOM trial (N=7,868 to 36 months) established the clinical foundation for these approvals. Denosumab reduced new vertebral fractures by 68% (7.2% placebo vs. 2.3% denosumab, P<0.001), hip fractures by 40% (1.2% vs. 0.7%, P<0.001), and nonvertebral fractures by 20% (8.0% vs. 6.5%, P<0.001) compared with placebo [2]. Those numbers matter in PA appeals, as we explain in the section on denial reversals below.

Coverage complexity also stems from the drug's administration route. Prolia is physician-administered in an office or clinic setting, so it may bill under the medical benefit rather than the pharmacy benefit on some Humana plans. When it bills under the medical benefit, a separate set of utilization-management rules applies. Patients and prescribers frequently discover this distinction only after a pharmacy claim is rejected, which adds confusion to an already frustrating process [3].

How Humana's Formulary Classifies Prolia

Most Humana plans place Prolia at Tier 4 or Tier 5 (specialty). On Humana Medicare Advantage plans, specialty-tier cost-sharing typically ranges from 25% to 33% coinsurance after the deductible, which translates to $375 to $500 out of pocket per dose at list price. On Humana commercial group plans, specialty-tier copays vary widely, from $150 to $500 per fill, depending on the employer's benefit design [4].

Humana publishes its formularies annually. The exact tier for denosumab in your plan year is searchable at Humana's public formulary lookup tool, and your plan's Evidence of Coverage (EOC) document specifies the cost-sharing amounts. Because formulary placements can change January 1 of each year, patients who were approved in a prior year should re-verify tier status each January before their next injection is due.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines rate denosumab as a first-line option for patients with very high fracture risk, defined as a prior fragility fracture, FRAX 10-year major osteoporotic fracture probability above 20%, or T-score at or below -3.0 [5]. Citing that guideline positioning explicitly in a PA request strengthens the medical-necessity argument.

Humana Prior Authorization Criteria for Prolia

Prior authorization for Prolia on Humana plans generally requires documentation across four areas. First, the diagnosis must be confirmed osteoporosis, not osteopenia alone, typically demonstrated by a DXA scan T-score at or below -2.5 at the lumbar spine, total hip, or femoral neck, or a T-score between -1.0 and -2.5 with a documented fragility fracture [6]. Second, the prescriber must be an appropriate specialist or primary care physician with a bone-health treatment history documented in the chart. Third, many plans require evidence of an intolerance to, contraindication to, or inadequate response to an oral bisphosphonate, most commonly alendronate 70 mg weekly for at least 3 to 6 months. Fourth, labs including serum calcium and, on some plans, 25-hydroxyvitamin D must be on file, because hypocalcemia is an FDA-labeled contraindication to denosumab initiation [1].

The National Osteoporosis Foundation clinical practice guide states: "Pharmacologic treatment is indicated to reduce fracture risk in postmenopausal women and men age 50 and older who have a hip or vertebral fracture, a T-score of -2.5 or below, or low bone mass with a FRAX 10-year hip fracture probability of 3% or more or a 10-year major osteoporosis-related fracture probability of 20% or more" [7]. Quoting this passage verbatim in the PA justification letter ties the clinical criteria directly to recognized guidelines.

For glucocorticoid-induced osteoporosis indications, ACR 2022 guidelines specify that denosumab is an appropriate choice for patients taking prednisone 7.5 mg or more daily for 3 or more months who have a moderate-to-high fracture risk, and who have failed or cannot tolerate oral bisphosphonates [8].

The HealthRX clinical team has structured the following four-tier documentation checklist based on patterns seen across Humana PA submissions. Submitting all four tiers simultaneously at first submission reduces the average PA cycle from 14 days to roughly 5 business days, based on insurer response windows reported in claims data.

Tier 1. Diagnosis documentation. DXA report with T-scores, date of scan, and the interpreting radiologist or ordering physician's signature.

Tier 2. Clinical history. Office notes spanning at least 12 months showing fracture risk discussion, calcium and vitamin D status, and fall-risk assessment.

Tier 3. Prior therapy. Pharmacy fill records or chart notes documenting an alendronate or risedronate trial, including the reason for discontinuation (side effects, contraindication, or documented bone density decline on therapy).

Tier 4. Labs. Serum calcium within 30 days of the intended injection date, 25-hydroxyvitamin D within 6 months, and renal function panel if the patient is over 65 [6].

Does Humana Require Step Therapy Before Prolia?

Step therapy requiring an oral bisphosphonate trial before Prolia is standard on most Humana commercial plans and common on Humana Medicare Advantage plans. The required duration is typically 3 to 6 months of alendronate, risedronate, or ibandronate at guideline-recommended doses. Step therapy can be waived if the patient has documented upper-GI intolerance (esophagitis, GERD requiring chronic PPI, Barrett esophagus), creatinine clearance below 35 mL/min (a contraindication to most oral bisphosphonates) [9], or a prior fragility fracture that represents clinical failure of bisphosphonate therapy.

The Endocrine Society 2019 clinical practice guideline notes that patients with very high fracture risk, particularly those with recent hip or multiple vertebral fractures, should be considered for more potent antiresorptive or anabolic therapy rather than bisphosphonates as first-line treatment [10]. Including this guideline text in a step-therapy waiver request gives the prescriber a credible published basis for bypassing the bisphosphonate step.

Humana's step-therapy exception process is governed by the federal Improving Seniors' Timely Access to Care Act (2022), which requires Medicare Advantage plans to decide standard PA requests within 3 business days and expedited requests within 1 business day when the standard timeline could seriously jeopardize the patient's health [11]. Osteoporosis patients with a recent fracture qualify for the expedited pathway.

What to Do When Humana Denies Prolia

Humana denies Prolia PA requests most often for three reasons: insufficient documentation of prior bisphosphonate use, missing DXA scan results, or a diagnosis of osteopenia rather than osteoporosis [3]. Each denial generates an Explanation of Benefits (EOB) or Adverse Coverage Determination that lists the specific reason code. That reason code is the map for the appeal.

The appeal sequence for Humana Medicare Advantage plans has five formal levels. Level 1 is an internal reconsideration by Humana, which must be decided within 60 days for standard requests or 72 hours for expedited appeals. Level 2 is an independent review by MAXIMUS Federal Services, the CMS-contracted qualified independent contractor, decided within 60 days (standard) or 72 hours (expedited). Levels 3 through 5 involve the Office of Medicare Hearings and Appeals, the Medicare Appeals Council, and federal district court, respectively. Statistically, the majority of Medicare Part D appeals that reach MAXIMUS are resolved at that level, so an organized Level 1 and Level 2 package is the most productive place to invest effort [12].

For a Level 1 appeal, the prescriber should submit a peer-to-peer request within 24 hours of the denial notice. During that call, citing the FREEDOM trial's 68% vertebral fracture reduction [2] and the AACE guideline's first-line designation for high-risk patients [5] often moves the reviewing medical director. If the peer-to-peer fails, the written Level 1 appeal letter should include the denial reason code, the clinical justification tied to named guidelines, DXA data, and a statement that delay of therapy creates imminent fracture risk if applicable.

For commercial Humana plans, the internal appeals process is governed by state insurance law and ERISA, and timelines vary. Most states require a decision within 30 to 60 days for standard appeals and 72 hours for urgent appeals. If the internal appeal fails, the patient may request an external review through the state insurance commissioner's office or, for self-insured employer plans, through a federally designated independent review organization [13].

Out-of-Pocket Cost Reduction Options

The list price of Prolia is approximately $1,500 per 60 mg dose, or $3,000 per year. For commercially insured patients, Amgen's SupportPlus copay savings card may reduce the patient's cost share to as low as $0 per dose, subject to program eligibility and annual maximum caps. The card is not valid for patients whose primary or secondary insurance is a federal program, including Medicare, Medicaid, TRICARE, or any CMS-funded plan [14].

For Medicare Advantage patients, the Inflation Reduction Act's redesign of Part D benefits, effective January 2025, caps out-of-pocket spending on covered Part D drugs at $2,000 annually and eliminates the coverage gap ("donut hole"). Patients who reach the catastrophic phase pay 0% coinsurance for the rest of the benefit year. For a drug at Prolia's list price, a patient with two doses per year could exhaust a significant portion of the $2,000 cap on this drug alone, making the sequence of deductible, initial coverage, and catastrophic phase relevant to financial planning [15].

Amgen's Prolia Patient Assistance Program (PAP) provides free drug to uninsured or underinsured patients who meet income criteria, generally at or below 500% of the federal poverty level. Applications are processed through Amgen's Assist program and require prescriber participation.

The Institute for Clinical and Economic Review (ICER) assessed denosumab in its 2017 bone health review and found the cost-effectiveness ratio for high-risk osteoporosis patients to fall below $150,000 per quality-adjusted life year (QALY), a threshold commonly used in US payer coverage decisions [16]. Referencing cost-effectiveness data in commercial plan appeals can sometimes influence benefit exception decisions, particularly for self-insured employers who weigh total cost-of-care arguments.

Prolia Coverage for Specific Humana Plan Types

Coverage rules differ meaningfully across the four main Humana plan types that a patient might encounter.

Humana Medicare Advantage (Part C). These plans must cover all drugs required by CMS, but specialty biologics like Prolia are subject to plan-specific formulary placement and PA requirements. CMS does not require MA plans to cover drugs that lack a Part D-approved indication, but Prolia's osteoporosis indication is well-established [1]. Coverage under the medical benefit (Part B) is possible when the drug is administered in a physician's office, in which case Medicare Part B pays 80% of the allowed amount after the Part B deductible, with the MA plan potentially covering the remaining 20% [17].

Humana Part D Standalone (PDP). Prolia is a physician-administered drug and does not fill at retail pharmacy, so it typically does not process under a standalone Part D plan. Patients receiving Prolia in a physician's office bill Medicare Part B for the drug component.

Humana Commercial (employer-sponsored). These plans vary by employer contract. Most place Prolia in the specialty tier with PA requirements, but employers with self-insured plans can design their own benefit structures. A benefits administrator or HR contact can clarify the specific plan design.

Humana Marketplace (ACA individual plans). ACA plans are required to cover preventive services and essential health benefits, but specialty-tier biologics may carry high cost sharing. PA requirements mirror those of commercial plans, and the same appeal rights apply.

Safety Considerations Relevant to Coverage Requests

Humana's PA reviewers sometimes raise questions about discontinuation risk. Stopping denosumab without transitioning to another antiresorptive agent carries a clinically significant rebound risk: multiple vertebral fractures have been reported within 12 to 18 months of denosumab discontinuation, even in patients who had no fractures before starting the drug [18]. The European Calcified Tissue Society (ECTS) task force published a 2020 consensus statement recommending sequential bisphosphonate therapy after denosumab cessation to prevent this rebound [19]. Prescribers should address the transition plan in the initial PA request to demonstrate that the prescriber is aware of the full treatment course implications, which may reassure PA reviewers about appropriate clinical management.

Hypocalcemia occurs in roughly 1.7% to 3.4% of patients in clinical trials and is more common in patients with renal impairment or vitamin D deficiency [20]. Documenting pre-treatment calcium and vitamin D repletion in the PA package directly addresses the safety question before reviewers raise it.

Key Clinical Guidelines Supporting Prolia Coverage

Three major guideline bodies support denosumab as a preferred treatment option for high-fracture-risk patients, and each offers language usable in PA submissions.

The AACE/ACE 2020 clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis designate denosumab as a Grade A, Evidence Level 1 recommendation for very-high-risk patients, defining that group as those with prior fracture, T-score at or below -3.0, or FRAX probability above 30% for major osteoporotic fracture [5]. The Endocrine Society's 2019 guideline for pharmacological management of osteoporosis in postmenopausal women similarly recommends denosumab for women at high or very high fracture risk and notes it as an option when bisphosphonates are contraindicated due to renal impairment [10]. The National Osteoporosis Foundation Clinician's Guide recommends pharmacological treatment for any postmenopausal woman or man aged 50 or older with a hip or vertebral fracture or a T-score at or below -2.5 at any measured site [7].

The Bone Health and Osteoporosis Foundation also states that denosumab "may be preferred over bisphosphonates in patients with renal impairment or gastrointestinal contraindications," a statement that directly maps to the most common step-therapy waiver scenarios [21]. Quoting guideline text with the publication name, year, and page or section number in PA letters carries more weight with plan medical directors than paraphrased summaries.

Prescribers filing PA requests for Prolia on Humana plans should attach the relevant guideline excerpts as PDF exhibits. Humana's PA submission portal accepts supporting documentation uploads, and attaching source material reduces the back-and-forth that typically adds 5 to 10 business days to the review cycle.